Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zai Completes $200 Million Follow-on Financing as It Nears Commercialization of Two Products

publication date: May 5, 2019

Zai Lab completed a $200 million follow-on financing, just eight months after its previous $150 million follow-on round. The company expects to launch two oncology products in China this year, a PARP inhibitor and an electric fields treatment for GBM. It already markets both products in Hong Kong. It will reserve more than one-quarter of its newest funding for business development. The funding was well-received: underwriters upped the number of ADSs available from 5 million to 7.8 million in response to investor interest. More details....

Stock Symbol: (NSDQ: ZLAB)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.